Comparing SNU Gastric Lines: SNU-1, SNU-5, SNU-16, and SNU-620

Gastric cancer exhibits remarkable heterogeneity, with diverse histological subtypes, molecular profiles, and clinical behaviors that complicate treatment selection and drug development. At Cytion, we recognize that effectively modeling this diversity requires access to multiple cell line models representing different aspects of gastric cancer biology. The SNU series of gastric cancer cell lines, established from Korean patients, encompasses this heterogeneity and provides essential tools for comparative studies. Understanding the distinct characteristics of each line enables researchers to select optimal models for specific research questions and develop more effective therapeutic strategies.

Key Takeaways

• SNU gastric lines represent diverse histological and molecular subtypes of gastric cancer
• Growth characteristics and morphology differ significantly between lines
• Drug sensitivity profiles vary based on genetic and epigenetic features
• Molecular markers including HER2, E-cadherin, and MSI status guide model selection
• Comparative studies across multiple lines improve translational relevance

Origins and Establishment of SNU Gastric Cancer Lines

The SNU gastric cancer cell line series was established at Seoul National University from Korean patients with gastric adenocarcinoma, representing diverse clinicopathological features encountered in this high-incidence population. These lines have become invaluable tools for gastric cancer research worldwide.

SNU-1 was derived from ascitic fluid of a patient with poorly differentiated gastric carcinoma. This line grows predominantly in suspension and exhibits aggressive behavior characteristic of advanced gastric cancer. Its poorly differentiated phenotype makes it suitable for studies of dedifferentiation and treatment resistance.

SNU-5 and SNU-16, similarly derived from ascites, harbor characteristic oncogenic amplifications - MET in SNU-5 and FGFR2 in SNU-16. These genetic features make them particularly valuable for targeted therapy research, serving as positive controls for MET and FGFR inhibitor sensitivity studies.

SNU-620 represents a more differentiated gastric cancer phenotype with adherent growth characteristics and retained epithelial markers. This line enables study of differentiated gastric cancer biology and comparison with more aggressive, dedifferentiated models.

Growth Characteristics and Culture Requirements

Understanding the distinct growth characteristics of each gastric cancer line is essential for experimental design and data interpretation. Culture conditions can significantly impact cell behavior, drug response, and molecular phenotype.

Suspension-growing lines like SNU-1, SNU-5, and SNU-16 require different handling than adherent cultures. These cells grow as floating aggregates or single cells, necessitating modified passaging protocols and assay adaptations. Viability assessment uses methods appropriate for suspension cells such as trypan blue exclusion or flow cytometry-based assays.

Doubling times vary substantially across the SNU panel, influencing experimental timelines and drug exposure protocols. SNU-16 exhibits particularly rapid proliferation, while SNU-620 shows slower, more controlled growth. These differences should be considered when designing comparative drug sensitivity studies.

For researchers seeking well-characterized adherent gastric cancer models, our AGS Cells (300408) provide an extensively validated platform with robust growth characteristics and extensive published literature supporting experimental design.

Published: 2023  |  Last reviewed: May 2026

Molecular and Genetic Profiles

The molecular characteristics of SNU gastric lines reflect the genetic diversity of gastric cancer and determine their suitability for specific research applications. Key oncogenic drivers, tumor suppressors, and molecular markers distinguish these lines.

MET amplification in SNU-5 drives constitutive receptor activation and dependency on MET signaling for survival and proliferation. This line shows dramatic sensitivity to MET inhibitors including crizotinib and capmatinib, serving as a positive control for MET-targeted drug screening.

FGFR2 amplification in SNU-16 similarly creates oncogenic dependency exploitable by FGFR inhibitors. Clinical trials with FGFR inhibitors in gastric cancer have shown promising results in FGFR2-amplified patients, and SNU-16 enables preclinical modeling of these therapeutic approaches.

E-cadherin (CDH1) expression varies across the SNU panel, with loss correlating with epithelial-mesenchymal transition and increased invasive potential. SNU-620 maintains E-cadherin expression consistent with its differentiated epithelial phenotype, while poorly differentiated lines show reduced or absent expression.

Drug Sensitivity Profiling

Comparative drug sensitivity profiling across multiple SNU lines identifies both broadly active agents and compounds with selectivity for specific molecular subtypes. This information guides patient stratification strategies for personalized medicine approaches.

Conventional chemotherapeutics including 5-fluorouracil, cisplatin, and paclitaxel show variable efficacy across SNU lines. Sensitivity patterns often correlate with proliferation rate, DNA repair capacity, and apoptotic pathway integrity. High-throughput screening across the panel identifies compounds with broad anti-gastric cancer activity.

Targeted agents show predictable sensitivity based on driver oncogene status. MET inhibitors potently suppress SNU-5 proliferation while showing minimal activity in MET-normal lines. FGFR inhibitors selectively target SNU-16 based on its FGFR2 amplification. These clear genotype-response correlations validate the targeted therapy paradigm.

Combination strategies can be optimized using panel-based screening. Synergy between chemotherapy and targeted agents may overcome resistance mechanisms, and testing across molecularly diverse lines identifies combinations with broad applicability versus those limited to specific subtypes.

Xenograft and In Vivo Models

Transitioning from in vitro culture to in vivo models enables assessment of tumor growth, metastasis, and drug efficacy in physiologically relevant contexts. SNU lines vary in their tumorigenicity and in vivo behavior.

Subcutaneous xenograft models using SNU lines in immunodeficient mice enable tumor growth measurement and drug efficacy assessment. Take rates and growth kinetics differ between lines, with aggressive poorly differentiated lines generally showing faster tumor establishment than differentiated models.

Orthotopic implantation into the gastric wall better recapitulates the tumor microenvironment and enables study of local invasion and peritoneal dissemination. This approach requires surgical expertise but provides more clinically relevant models for advanced gastric cancer research.

Our HGC-27 Cells (300436) offer an additional gastric carcinoma model with undifferentiated characteristics suitable for xenograft studies and comparative analysis with SNU lines.

Biomarker and Companion Diagnostic Development

SNU gastric cancer lines enable development and validation of predictive biomarkers for treatment selection. Correlating drug response with molecular features identifies candidate biomarkers for clinical implementation.

HER2 status determination using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) can be validated in cell line models before clinical application. Cell lines with known HER2 status serve as controls for assay development and quality assurance.

Gene expression signatures predicting response to specific therapies can be derived from cell line drug sensitivity data and validated in independent cohorts. Computational approaches integrate multi-omic data to identify robust predictive signatures.

Circulating biomarker assays including circulating tumor DNA (ctDNA) analysis can be developed using cell line-derived materials. Spiking experiments with known quantities of cell line DNA into plasma matrices enable assay sensitivity and specificity optimization.

Recommended Products for Gastric Cancer Research:

• AGS Cells (300408) - Well-characterized gastric adenocarcinoma
• HGC-27 Cells (300436) - Undifferentiated gastric carcinoma
• DMEM High Glucose (820300a) - Standard culture medium
• Freeze medium CM-ACF (800650) - Cryopreservation solution